Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn’s Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY) Get access

• Abstracts
• Supplementary data

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis

• Abstracts
• Supplementary data

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study Get access

• Abstracts
• Supplementary data

Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment Get access

• Abstracts
• Supplementary data

Antigen-driven expansion of public clonal T cell populations in inflammatory bowel diseases Get access

• Abstract
• Supplementary data

US and European Patient and Health Care Professional Perspectives on Fatigue in Ulcerative Colitis and Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey

• Abstract
• Lay summary
• Supplementary data

TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL

• Abstract

BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

• Abstract

TWO-YEAR RESULTS OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION THERAPY - FROM LIBERTY-CD AND LIBERTY-UC

• Abstract

PATIENT-REPORTED DISEASE CONTROL IN MODERATE-TO-SEVERE CROHN’S DISEASE AND ULCERATIVE COLITIS: RESULTS FROM THE COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

• Abstract

IMPACT OF IMMUNOGENICITY ON CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-UC STUDY

• Abstract

CROHN’S DISEASE AND BOWEL URGENCY: US AND EUROPEAN PATIENT AND HEALTHCARE PROFESSIONAL PERSPECTIVES FROM THE COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

• Abstract

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies

• Abstracts
• Supplementary data

Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12

• Abstracts
• Lay summary
• Supplementary data

Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program

• Abstracts
• Supplementary data

Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib

Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study

• Abstract
• Lay summary
• Supplementary data

The microRNA Expression in Crypt-Top and Crypt-Bottom Colonic Epithelial Cell Populations Demonstrates Cell-Type Specificity and Correlates with Endoscopic Activity in Ulcerative Colitis

• Abstract
• Supplementary data

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials

• Abstracts
• Supplementary data

Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

• Abstracts
• Supplementary data